Delivery Order SPE2DR25D3404-SPE2DR26F5V3E
- Not listed
- The Defense Logistics Agency awarded a $1,241.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL, 200 mL unit). This competitive award, which carries an ultimate completion date of December 31, 2025, represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's distribution facility in...
- The Defense Logistics Agency awarded a $1,154.95 delivery order to AmerisourceBergen Drug Corp on December 12, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 ml) pharmaceutical product, with completion scheduled for December 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 ml in 200 ml units, with a ceiling value of $2,147.31. This competitively awarded, firm fixed-price delivery order is set to be completed by September 19, 2025, with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency (DLA) on September 24, 2025, for the supply of Ropivacaine 0.2% (200 mg/100 mL) in 100 mL units, with a ceiling value of $1,419.66 and a firm fixed price structure. The contract is scheduled for ultimate completion on September 25, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order was issued with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL) in 200 mL units at a firm fixed price of $4,058.09. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The work is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,136.89 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL in 200 mL units). This non-set-aside, firm fixed-price delivery order was competitively awarded on December 5, 2025, with an ultimate completion date of December 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,162.46 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml, 200 ml units) with a completion date of December 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Ropivacaine 0.2% in 400 mg/200 ml vials totaling 200 ml, with a ceiling value of $1,385.94. This competitively awarded, non-set-aside contract is classified as a firm fixed-price delivery order with an ultimate completion date of December 16, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a $5,150.36 delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL in 200 mL units). This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of December 31, 2025. The product will be performed and delivered from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,790.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). The contract, which is a non-set-aside competitive award with an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order will be fulfilled from the vendor's facility in Conshohocken,...
- SPE2DR25D3404Indefinite Delivery Contract
- SPE2DR25D3404-SPE2DR26F5V3EDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,491.09 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% 400 mg/200 ml in 200 ml units. This is a firm fixed-price, non-set-aside contract with a completion date of January 7, 2026, following the award date of January 6, 2026. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. The IDC serves as a comprehensive vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally, encompassing specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. As a major pharmaceutical distributor, AmerisourceBergen has demonstrated consistent capability to meet federal procurement requirements through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 1/5/26 |